Moderna (MRNA) said Friday it has completed the construction of a research and production facility in Japan but will not proceed with a separate plan to build an mRNA drug substance manufacturing site.
The completed facility, led by Moderna Enzymatics, is located at Shonan Health Innovation Park in Kanagawa Prefecture in Japan and is focused on mRNA research and manufacturing using cell-free DNA synthesis technology, the company said.
Moderna cited evolving global and domestic conditions as the reason for canceling the separate manufacturing site but said it may revisit the project in the future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。